Neurotrope BioScience Inc. is developing Alzheimer's disease therapeutics targeting protein kinase C, an enzyme that could play a central role in pathology upstream of amyloid plaques and neurofibrillary tangles. The potential mechanism could explain the limited success of amyloid-targeted therapies.

Most companies pursuing AD develop therapeutics to prevent or remove the amyloid plaques or neurofibrillary tangles found in AD brains. Yet these plaques and tangles do not correlate with degree of dementia during life, and antibody therapies that reduced plaques did not improve dementia.